Substantial confusion exists about types and amounts of fat in the diet and their impact on cardiovascular risk. Understanding fats and their food sources, along with some of the inherent challenges in studying nutrition, may help practitioners and consumers wade through the confusion. In this CardioNutrition episode, Robert Ostfeld, MD, MSc, FACC, and Kevin Klatt, PhD, RD, discuss the skinny on fats and omega 3s. For more, visit www.acc.org/CardioNutrition.

In this CardioNutrition episode, Robert Ostfeld, MD, MSc, FACC, and Kim Allan Williams, Sr., MD, MACC, discuss what the ACC dietary guidelines say. For more, visit www.acc.org/CardioNutrition.

In this CardioNutrition episode, host Robert Ostfeld, MD, MSc, FACC, Director of Preventive Cardiology at Montefiore Health System, and Professor of Medicine at the Albert Einstein College of Medicine, introduces the CardioNutrition program. For more, visit www.acc.org/CardioNutrition.

What is the difference between a whole and refined carb? Are carbs healthy or unhealthy? In this CardioNutrition episode, Robert Ostfeld, MD, MSc, FACC, and Walter Willett, MD, PhD, discuss carbs, fiber, and grains—oh my! For more, visit www.acc.org/CardioNutrition.

In this episode, Alanna Morris, MD, MSc, FACC; Javed Butler, MBBS, FACC; John McMurray, MD, FACC; and Muthiah Vaduganathan, MD, FACC, discuss the role of sodium-glucose transport protein 2 inhibitors in the new hope in heart failure (HF). Visit the Clinical Spotlight Series: Shining a Light on New HF Pharmacotherapies online course page for more information and resources. Educational Support provided by AstraZeneca, Cytokinetics, Merck Sharp & Dohme Corp., and Novartis Pharmaceuticals Corporation.

In this episode, Kim Eagle, MD, MACC, asks Matthew Martinez, MD, FACC, and Steve Ommen, MD, FACC, all of the questions you wish you could ask about hypertrophic cardiomyopathy and the new ACC guidelines. 

In this episode, Frederick Ruberg, MD, and Mathew Maurer, MD, discuss key topics in cardiac amyloidosis such as the evolving understanding of the epidemiology of the disease, contemporary approaches to diagnosis with an emphasis on noninvasive means, disease course and management of heart failure and conduction disease, as well as the recently approved therapeutics for the two major types of cardiac amyloidosis: light-chain and transthyretin. (Educational grant support is provided by Janssen Oncology.)

In this episode, JoAnn Lindenfeld, MD, FACC; Vinay Badhwar, MD, FACC; Sammy Elmariah, MD, MPH, FACC; and Rebecca T. Hahn, MD, FACC, discuss the 2020 Expert Consensus Decision Pathway for mitral regurgitation.

In this episode, Michael Mack, MD, MACC, Kim Eagle, MD, MACC, and Rebecca Hahn, MD, FACC, discuss important changes in the 2020 valvular guideline update.

In this episode, Paul Grayburn, MD, FACC, and Rebecca Hahn, MD, FACC, discuss the five key elements of a comprehensive mitral regurgitation echocardiogram: etiology/morphology, severity, left ventricular size and function, left atrial size and pulmonary artery pressure estimate, and anatomic suitability for intervention.